Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect. / Rodell, Anders Bertil; Aanerud, Joel; Braendgaard, Hans; Gjedde, Albert.

In: Frontiers in Neuroenergetics, Vol. 4, No. Article 8, 2012, p. 1-12.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rodell, AB, Aanerud, J, Braendgaard, H & Gjedde, A 2012, 'Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect', Frontiers in Neuroenergetics, vol. 4, no. Article 8, pp. 1-12. https://doi.org/10.3389/fnene.2012.00008

APA

Rodell, A. B., Aanerud, J., Braendgaard, H., & Gjedde, A. (2012). Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect. Frontiers in Neuroenergetics, 4(Article 8), 1-12. https://doi.org/10.3389/fnene.2012.00008

Vancouver

Rodell AB, Aanerud J, Braendgaard H, Gjedde A. Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect. Frontiers in Neuroenergetics. 2012;4(Article 8):1-12. https://doi.org/10.3389/fnene.2012.00008

Author

Rodell, Anders Bertil ; Aanerud, Joel ; Braendgaard, Hans ; Gjedde, Albert. / Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect. In: Frontiers in Neuroenergetics. 2012 ; Vol. 4, No. Article 8. pp. 1-12.

Bibtex

@article{0a656842fc154680b2d69dae4e19f1ca,
title = "Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect",
abstract = "We tested the claim that inter-individual CBF variability in Alzheimer's disease (AD) is substantially reduced after correction for arterial carbon dioxide tension (PaCO(2)). Specifically, we tested whether the variability of CBF in brain of patients with AD differed significantly from brain of age-matched healthy control subjects (HC). To eliminate the CO(2)-induced variability, we developed a novel and generally applicable approach to the correction of CBF for changes of PaCO(2) and applied the method to positron emission tomographic (PET) measures of CBF in AD and HC groups of subjects. After correction for the differences of CO(2) tension, the patients with AD lost the inter-individual CBF variability that continued to characterize the HC subjects. The difference (¿K(1)) between the blood-brain clearances (K(1)) of water (the current measure of CBF) and oxygen (the current measure of oxygen clearance) was reduced globally in AD and particularly in the parietal, occipital, and temporal lobes. We then showed that oxygen gradients calculated for brain tissue were similar in AD and HC, indicating that the low residual variability of CBF in AD may be due to low functional demands for oxidative metabolism of brain tissue rather than impaired delivery of oxygen.",
author = "Rodell, {Anders Bertil} and Joel Aanerud and Hans Braendgaard and Albert Gjedde",
year = "2012",
doi = "10.3389/fnene.2012.00008",
language = "English",
volume = "4",
pages = "1--12",
journal = "Frontiers in Neuroenergetics",
issn = "1662-6427",
publisher = "Frontiers Research Foundation",
number = "Article 8",

}

RIS

TY - JOUR

T1 - Low Residual CBF Variability in Alzheimer's Disease after Correction for CO(2) Effect

AU - Rodell, Anders Bertil

AU - Aanerud, Joel

AU - Braendgaard, Hans

AU - Gjedde, Albert

PY - 2012

Y1 - 2012

N2 - We tested the claim that inter-individual CBF variability in Alzheimer's disease (AD) is substantially reduced after correction for arterial carbon dioxide tension (PaCO(2)). Specifically, we tested whether the variability of CBF in brain of patients with AD differed significantly from brain of age-matched healthy control subjects (HC). To eliminate the CO(2)-induced variability, we developed a novel and generally applicable approach to the correction of CBF for changes of PaCO(2) and applied the method to positron emission tomographic (PET) measures of CBF in AD and HC groups of subjects. After correction for the differences of CO(2) tension, the patients with AD lost the inter-individual CBF variability that continued to characterize the HC subjects. The difference (¿K(1)) between the blood-brain clearances (K(1)) of water (the current measure of CBF) and oxygen (the current measure of oxygen clearance) was reduced globally in AD and particularly in the parietal, occipital, and temporal lobes. We then showed that oxygen gradients calculated for brain tissue were similar in AD and HC, indicating that the low residual variability of CBF in AD may be due to low functional demands for oxidative metabolism of brain tissue rather than impaired delivery of oxygen.

AB - We tested the claim that inter-individual CBF variability in Alzheimer's disease (AD) is substantially reduced after correction for arterial carbon dioxide tension (PaCO(2)). Specifically, we tested whether the variability of CBF in brain of patients with AD differed significantly from brain of age-matched healthy control subjects (HC). To eliminate the CO(2)-induced variability, we developed a novel and generally applicable approach to the correction of CBF for changes of PaCO(2) and applied the method to positron emission tomographic (PET) measures of CBF in AD and HC groups of subjects. After correction for the differences of CO(2) tension, the patients with AD lost the inter-individual CBF variability that continued to characterize the HC subjects. The difference (¿K(1)) between the blood-brain clearances (K(1)) of water (the current measure of CBF) and oxygen (the current measure of oxygen clearance) was reduced globally in AD and particularly in the parietal, occipital, and temporal lobes. We then showed that oxygen gradients calculated for brain tissue were similar in AD and HC, indicating that the low residual variability of CBF in AD may be due to low functional demands for oxidative metabolism of brain tissue rather than impaired delivery of oxygen.

U2 - 10.3389/fnene.2012.00008

DO - 10.3389/fnene.2012.00008

M3 - Journal article

C2 - 22783187

VL - 4

SP - 1

EP - 12

JO - Frontiers in Neuroenergetics

JF - Frontiers in Neuroenergetics

SN - 1662-6427

IS - Article 8

ER -

ID: 44913566